Myasthenie.com

Neurology. 2025 Apr 8;104(7_Supplement_1):3887. doi: 10.1212/WNL.0000000000211303. Epub 2025 Apr 7.

ABSTRACT

OBJECTIVE: To compare hospitalization outcomes between the 1-year before and after efgartigimod initiation in patients with myasthenia gravis (MG).

BACKGROUND: While significant reduction in hospitalizations and exacerbations after efgartigimod initiation was observed in the ADAPT/ADAPT+ trials, evidence in clinical practice is limited.

DESIGN/METHODS: In this retrospective cohort study, patients with MG who initiated and continued efgartigimod for ≥1-year were identified from an integrated dataset of US medical and pharmacy claims (based on information licensed from IQVIA: Longitudinal Access and Adjudication Data [LAAD] for the period April 2016-January 2024, reflecting estimates of real-world activity [all rights reserved]) and data from the My VYVGART Path patient support program (PSP). Hospitalizations were evaluated based on inpatient claims recorded during 1-year before and after efgartigimod initiation (index date), and further classified. Exacerbations were defined as inpatient encounters with ICD-10 codes for MG with exacerbation. Crises were defined as intensive care unit admissions with ICD-10 codes for acute respiratory failure. Myasthenia Gravis Activities of Daily Living (MG-ADL) scores before (≤90 days) and after (≤365 days) index were obtained from the PSP.

RESULTS: 440 patients were included. Mean (SD) age was 60.6 (15.0) years and 46% (n=201/440) were female. Compared to the 1-year before index, mean hospitalization events were significantly reduced in the year after index by 52% (pre: 0.65, post: 0.31, P

Source: https://pubmed.ncbi.nlm.nih.gov/4019438 ... t9+e462414